Pharming Group Past Earnings Performance

Past criteria checks 0/6

Pharming Group's earnings have been declining at an average annual rate of -56.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 6.5% per year.

Key information

-56.7%

Earnings growth rate

-57.1%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate6.5%
Return on equity-7.9%
Net Margin-6.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pharming Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0QCO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24286-1819572
30 Jun 24278-1318772
31 Mar 24258-1118472
31 Dec 23245-1117569
30 Sep 23219-2216068
30 Jun 23206-1615760
31 Mar 23202-214053
31 Dec 222061412753
30 Sep 222043011069
30 Jun 222022110070
31 Mar 22202119470
31 Dec 21199169165
30 Sep 21200228848
30 Jun 21200318344
31 Mar 21202377941
31 Dec 20212387639
30 Sep 20212447533
30 Jun 20202467032
31 Mar 20202426933
01 Jan 20189416633
30 Sep 19175385838
30 Jun 19175346036
31 Mar 19158295532
31 Dec 18155295433
30 Sep 18152-295627
30 Jun 18138-445325
31 Mar 18128-805324
31 Dec 17108-914522
30 Sep 1776-533221
30 Jun 1747-472120
31 Mar 1731-211317
31 Dec 1617-18816
30 Sep 1612-16617
30 Jun 1612-15616
31 Mar 1613-14617
31 Dec 1512-11515
30 Sep 15298614
30 Jun 15279514
31 Mar 152310413
31 Dec 1426-7414
30 Sep 146-29315
30 Jun 146-35314
31 Mar 1411-35315
31 Dec 139-21314

Quality Earnings: 0QCO is currently unprofitable.

Growing Profit Margin: 0QCO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0QCO is unprofitable, and losses have increased over the past 5 years at a rate of 56.7% per year.

Accelerating Growth: Unable to compare 0QCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0QCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0QCO has a negative Return on Equity (-7.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.